Oscar Tahuahua/X
Jun 16, 2025, 11:26
Oscar Tahuahua: Advances in Molecular Pathology and Therapy of NSCLC
Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico, shared a post on X:
“Advances in Molecular Pathology and Therapy of NSCLC.
Precision oncology is no longer optional. This review maps the molecular landscape of NSCLC (EGFR, ALK, KRAS, etc.), resistance, spatial omics and AI, and shows how biology is reshaping lung cancer treatment.
Resistance in NSCLC isn’t accidental, it’s adaptive. This explains how EGFR T790M, KRAS/STK11, EMT and an immunosuppressive TME reshape tumor biology under treatment pressure.”
Title: Advances in molecular pathology and therapy of non-smallcell lung cancer
Authors: Qing Huang, Yuanxiang Li, Yingdan Huang, Jingyi Wu, Wendai Bao, Chang Xue, Xiaoyu Li, Shuang Dong, Zhiqiang Dong, Sheng Hu
Read The Full Article at Signal Transduction and Targeted Therapy.
More posts featuring Oscar Tahuahua on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 6, 2025, 07:47
Jul 6, 2025, 07:09
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52